New and emerging treatments for irritable bowel syndrome and functional dyspepsia

Expert Opinion on Emerging Drugs

Volumn 7, Issue 1, 2002, Pages 91-98

  Talley, Nicholas J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANALGESIC AGENT; BULKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOTROPIN RECEPTOR; DARIFENACIN; DESIPRAMINE; DEXLOXIGLUMIDE; FEDOTOZINE; GASTROINTESTINAL AGENT; HYOSCYAMINE; LAXATIVE; LEUPRORELIN; LOPERAMIDE; NORTRIPTYLINE; OPIATE AGONIST; PEPPERMINT OIL; PROKINETIC AGENT; PRUCALOPRIDE; RECEPTOR BLOCKING AGENT; SEROTONIN 1 AGONIST; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 AGONIST; SEROTONIN UPTAKE INHIBITOR; SPASMOLYTIC AGENT; TACHYKININ RECEPTOR ANTAGONIST; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; ZAMIFENACIN;

ABDOMINAL PAIN; CONSTIPATION; DIARRHEA; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; HEART ARRHYTHMIA; HUMAN; IRRITABLE COLON; LIVER TOXICITY; NAUSEA; PSYCHOTHERAPY; REVIEW;

EID: 0036074963     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.7.1.91     Document Type: Review

References (63)

1. Irritable bowel syndrome: A technical review for guidelines development
2. New drug classes: Neuroenteric modulators for the irritable bowel syndrome
3. Treatment of irritable bowel syndrome: A review of randomised controlled trials
4. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome
5. Mebeverine decreases mass movements and stool frequency in lactulose-induced diarrhoea
6. Muscarinic antagonists in development for disorders of smooth muscle function
7. Peppermint oil for irritable bowel syndrome: A critical review and meta-analysis
8. Evidence-based data on pain relief with antidepressants
9. Treatment of functional gastrointestinal disorders with antidepressant medications: A meta-analysis
10. A double-blind randomised placebo-controlled crossover trial of citalopram, a selective serotonin 5-hydroxytryptamine reuptake inhibitor, in irritable bowel syndrome
11. Hypersensitivity and hyperreactivity in the irritable bowel syndrome: An opportunity for drug discovery
12. Management of irritable bowel syndrome: Novel approaches to the pharmacology of gut motility
13. New and future drugs in nervegut dysfunction
14. Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study
15. Efficacy and safety of the peripheral κ agonist fedotozine versus placebo in the treatment of functional dyspepsia
16. Effect ofleuprolide acetate in treatment of abdominal pain and nausea in premenopausal women with functional bowel disease: A double-blind, placebocontrolled, randomised study
17. Peripheral actions of tachykinins
18. Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone
19. A somatostatin analog inhibits afferent pathways mediating perception of rectal distension
20. Anticonvulsant drugs for acute and chronic pain
21. Towards identifying optimal doses for α-2 adrenergic modulation of colonic and rectal motor and sensory function
22. Pharmacologic treatment of the irritable bowel syndrome: A systematic review of randomised, controlled trials
23. Bran and irritable bowel syndrome: Time for reappraisal
24. Management of the irritable bowel syndrome
25. Tegaserod: A new 5-HT4 agonist
26. Tegaserod
27. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome
28. 4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation
29. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder
30. The CCK A receptor-antagonist dexloxiglumide in the treatment of IBS
31. Therpeutic effects of loxiglumide, a cholecystokinin antagonist, on chronic constipation in elderly patients. Prospective, randomised, double blind controlled trial
32. Colchicine is an effective treatment for patients with chronic constipation: An open-label trial
33. Misoprostol in the treatment of chronic refactory constipation: Results of a long-term open label trial
34. Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans
35. Role of loperamide and placebo in management of irritable bowel syndrome (IBS)
36. Loperamide improves anal sphincter function and continence after restorative proctocolectomy
37. Idiopathic bile acid malabsorption: Qualitative and quantitative clinical features and response to cholestyramine
38. Post-cholecystectomy diarrhoea: Evidence of bile acid malabsorption assessed by SeHCAT test
39. Bile acid malabsorption in persistent diarrhoea
40. 3 receptor antagonism with ondansetron as treatment for diarrhoea-predominant irritable bowel syndrome. A pilot study
41. Efficacy and safety of alosetron in women with irritable bowel syndrome: A randomised placebo-controlled trial
42. Lotrenex and the FDA: An erosion of integrity
43. 4 receptor antagonist SB-207266 on gastrointestinal motor and sensory function in humans
44. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome
45. A controlled, double-blind, randomised study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome
46. Does Beano prevent gas? A double-blind, crossover study of oral α-galactosidase to treat dietary oligosaccaride intolerance
47. Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome
48. Initial management strategies for dyspepsia
49. Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: A meta-analysis
50. The influence of cisapride on gastric tone and perception of gastric distension
51. Influence of sumitriptan on gastric fundus tone and on the perception of gastric distension in man
52. Modulation of gastric sensory and motor functions by nitrregic and α-2 adrenergic agents
53. 4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects
54. A Phase II placebo controlled randomised trial with tegaserod in functional dyspepsia patients with normal gastric emptying
55. Perception of changes in wall tension of the proximal stomach in humans
56. Failure of a motilin receptor agonist (ABT-229) to relieve symptoms of functional dyspepsia in patients with and without delayed gastric emptying: A randomised double blind placebo controlled trial
57. Treatment of the irritable bowel syndrome
58. The irritable bowel syndrome
59. Psychological treatment for irritable bowel syndrome: A critique of controlled treatment trials
60. Irritable bowel syndrome. Practical management
61. Treatment of irritable bowel syndrome with Chinese herbal medicine. A randomised controlled trial
62. Acupuncture treatment for irritable bowel syndrome. A double-blind controlled study